Improved bacterial expression of the human P form phenolsulfotransferase: Applications to drug metabolism

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1180-1185

  Lewis, Amy J ^a   Kelly, Margaret M ^a   Walle, U Kristina ^a   Eaton, E Alison ^a   Falany, Charles N ^b   Walle, Thomas ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of Alabama at Birmingham   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; ANTIPAIN; ARYL SULFOTRANSFERASE; BENZYLSULFONYL FLUORIDE; BOVINE SERUM ALBUMIN; COMPLEMENTARY DNA; DITHIOTHREITOL; GLYCEROL; ISOPRENALINE; ISOPROPYL THIOGALACTOSIDE; MINOXIDIL; PARACETAMOL; PEPSTATIN; QUERCETIN;

ARTICLE; BACTERIUM; DRUG METABOLISM; DRUG SULFATION; ENZYME ACTIVITY; EXPRESSION VECTOR; HUMAN; LIVER CYTOSOL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ARYLSULFOTRANSFERASE; BACTERIA; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ENZYME STABILITY; HUMANS; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); BOVINAE;

EID: 0030459495     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. G. J. Mulder and W. B. Jakoby: Sulfation. In "Conjugation Reactions in Drug Metabolism: An Integrated Approach, Substrates, Co-Substrates, Enzymes and Their Interactions In Vivo and In Vitro" (G. J. Mulder, ed.), pp. 107-161. Taylor & Francis, London, 1990.
2. C. N. Falany: Molecular enzymology of human liver cytosolic sulfotransferases. Trends Pharmacol. Sci. 12, 255-259 (1991).
3. R. Weinshilboum and D. Otterness: Sulfotransferase enzymes. In "Handbook Experimental Pharmacology," vol. 112, pp. 45-78. Springer-Verlag, Berlin, 1994.
4. K. D. Meisheri, G. A. Johnson, and L. Puddington: Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem. Pharmacol. 45, 271-279 (1993).
5. J. A. Miller: Sulfonation in chemical carcinogenesis - history and present status. Chem. Biol. Interact. 92, 329-341 (1994).
6. M. Abu-Zeid, Y. Yamazoe, and R. Kato: Sulfotransferase-mediated DNA binding of N-hydroxyarylamines(amides) in liver cytosols from human and experimental animals. Carcinogenesis 13, 1307-1314 (1992).
7. R. A. H. J. Gilissen, R. Hume, J. H. N. Meerman, and M. W. H. Coughtrie: Sulphation of N-hydroxy-4-aminobiphenyl and N-hydroxy-4-acetylaminobiphenyl by human foetal and neonatal sulphotransferase. Biochem. Pharmacol. 48, 837-840 (1994).
8. H.-C. Chou, N. P. Lang, and F. F. Kadlubar: Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res. 55, 525-529 (1995).
9. C. M. King: Tamoxifen and the induction of cancer. Carcinogenesis 16, 1449-1454 (1995).
10. 32P-postlabeling and the use of pentachlorophenol for a novel metabolic activation pathway of diethylstilbestrol and its dimethyl ether in mouse liver: likely α-hydroxylation of ethyl group(s) followed by sulfate conjugation. Carcinogenesis 16, 2643-2648 (1995).
11. T. Walle, E. A. Eaton, and U. K. Walle: Quercetin, a potent and specific inhibitor of the human P form phenolsulfotransferase. Biochem. Pharmacol. 50, 731-734 (1995).
12. E. A. Eaton, U. K. Walle, A. J. Lewis, T. Hudson, A. A. Wilson, and T. Walle: Flavonoids, potent inhibitors of the human P form phenolsulfotransferase: potential role in drug metabolism and chemoprevention. Drug Metab. Dispos. 24, 232-237 (1996).
13. N. R. C. Campbell, J. A. Van Loon, and R. M. Weinshilboum: Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isoenzymes of the thermostable form. Biochem. Pharmacol. 36, 1435-1446 (1987).
14. C. N. Falany, M. E. Vazquez, J. A. Heroux, and J. A. Roth: Purification and characterization of human liver phenol-sulfating phenol sulfotransferase. Arch. Biochem. Biophys. 278, 312-318 (1990).
15. C. N. Falany, W. Zhuang, and J. L. Falany: Characterization of expressed human phenol-sulfating phenol sulfotransferase: effect of mutating cys70 on activity and thermostability. Chem. Biol. Interact. 92, 57-66 (1994).
16. C. N. Falany, J. Wheeler, T. S. Oh, and J. L. Falany: Steroid sulfation by expressed human cytosolic sulfotransferases. J. Steroid Biochem. Mol. Biol. 48, 369-375 (1994).
17. J. Sambrook, E. F. Fritsch, and T. Maniatis: "Molecular Cloning: A Laboratory Manual," 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
18. U. K. Walle, G. R. Pesola, and T. Walle: Stereoselective sulphate conjugation of salbutamol in humans - comparison of hepatic, intestinal and platelet activity. Br. J. Clin. Pharmacol. 35, 413-418 (1993).
19. E. Harlow and D. Lane: "Antibodies: A Laboratory Manual." Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988.
20. J. A. Heroux, C. N. Falany, and J. A. Roth: Immunological characterization of human phenol sulfotransferase. Mol. Pharmacol. 36, 29-33 (1989).
21. A. Foldes and J. L. Meek: Rat brain phenolsulfotransferase - partial purification and some properties. Biochim. Biophys. Acta 327, 365-374 (1973).
22. J. A. Shwed, U. K. Walle, and T. Walle: HepG2 cell line as a human model for sulfate conjugation of drugs. Xenobiotica 22, 973-982 (1992).
23. M. P. Deutscher: Maintaining protein stability. Methods Enzymol. 182, 83-89 (1990).
24. J. D. Dignam: Preparation of extracts from higher eukaryotes. Methods Enzymol. 182, 194-202 (1990).
25. F. A. O. Marston: The purification of eukaryotic polypeptides synthesized in Escherichia coli. Biochem. J. 240, 1-12 (1986).
26. C. H. Schein and M. H. M. Noteborn: Production of soluble recombinant proteins in bacteria. Biotechnology 7, 1141-1148 (1989).
27. J. B. Chaudhuri: Refolding recombinant proteins: process strategies and novel approaches. Ann. N.Y. Acad. Sci. 721, 374-385 (1994).
28. X. Chen, Y.-S. Yang, Y. Zheng, B. M. Martin, M. W. Duffel, and W. B. Jakoby: Tyrosine-ester sulfotransferase from rat liver: bacterial expression and identification. Protein Expr. Purif. 3, 421-426 (1992).
29. M. E. Veronese, W. Burgess, D. Cruickshank, L. Samson, X. Zhu, and M. E. McManus: Heterologous systems for expression of mammalian sulfotransferases. Chem. Biol. Interact. 92, 77-85 (1994).
30. G. R. Pesola and T. Walle: Stereoselective sulfate conjugation of isoproterenol in humans - comparison of hepatic, intestinal and platelet activity. Chirality 5, 602-609 (1993).
31. C. Reiter, G. Mwaluko, J. Dunnette, J. Van Loon, and R. Weinshilboum: Thermolabile and thermostable human platelet phenol sulfotransferase - substrate specificity and physical separation. Naunyn-Schmiedebergs Arch. Pharmacol. 324, 140-147 (1983).
32. N. R. C. Campbell, J. A. Van Loon, R. S. Sundaram, M. M. Ames, C. Hansch, and R. Weinshilboum: Human and rat liver phenol sulfotransferase: structure-activity relationships for phenolic substrates. Mol. Pharmacol. 32, 813-819 (1987).
33. R. S. Sundaram, C. Szumlanski, D. Otterness, J. A. Van Loon, and R. M. Weinshilboum: Human intestinal phenol sulfotransferase: assay conditions, activity levels and partial purification of the thermolabile form. Drug Metab. Dispos. 17, 255-264 (1989).
34. P. E. Kudlacek, R. J. Anderson, D. K. Liebentritt, G. A. Johnson, and C. J. Huerter: Human skin and platelet minoxidil sulfotransferase activities: biochemical properties, correlations and contribution of thermolabile phenol sulfotransferase. J. Pharmacol. Exp. Ther. 273, 582-590 (1995).
35. L. Varin, F. Marsolais, and N. Brisson: Chimeric flavonol sulfotransferases define a domain responsible for substrate and position specificities. J. Biol. Chem. 270, 12498-12502 (1995).
36. W.-X. A. Guo, Y.-S. Yang, X. Chen, P. McPhie, and W. B. Jakoby: Changes in substrate specificity of the recombinant form of phenol sulfotransferase IV (tyrosine-ester sulfotransferase). Chem. Biol. Interact. 92, 25-31 (1994).
37. Y. Yamazoe, K. Nagata, S. Ozawa, and R. Kato: Structural similarity and diversity of sulfotransferases. Chem. Biol. Interact. 92, 107-117 (1994).